ArticleJournal of feline medicine and surgery2020
Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.
Article in Journal of feline medicine and surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial.Journal of feline medicine and surgery · 2025Article
- Owner's Perspective About the Use of Mirtazapine Transdermal Ointment in Cats-A Survey-Based Study.Animals : an open access journal from MDPI · 2025Article
- Quantification of defecation frequency in cats with and without chronic kidney disease.Journal of feline medicine and surgery · 2025Article
- Pharmacokinetics of a Single Transdermal Dose of Mirtazapine in Rhesus Macaques (Comparative medicine · 2023Article
- 2022 ISFM/AAFP Cat Friendly Veterinary Environment Guidelines.Journal of feline medicine and surgery · 2022Article
- 2022 ISFM Consensus Guidelines on Management of the Inappetent Hospitalised Cat.Journal of feline medicine and surgery · 2022Article
- Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.Animals : an open access journal from MDPI · 2022Review
- Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre Retrospective Study.Animals : an open access journal from MDPI · 2022Article
- Appetite-stimulating effects of once-daily omeprazole in cats with chronic kidney disease: Double-blind, placebo-controlled, randomized, crossover trial.Journal of veterinary internal medicine · 2021Article
- A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.Journal of veterinary pharmacology and therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesThe aim of this study was to assess the appetite stimulation properties of compounded transdermal mirtazapine (CTM) in cats with chronic kidney disease (CKD).
methodsTwo sequential double-blind placebo-controlled crossover prospective studies were performed in client-owned cats with stable stage 2 or 3 CKD and a history of decreased appetite. In the first study nine CKD cats were randomized to receive 3.75 mg/0.1 ml CTM gel or placebo on the inner pinna every other day for 3 weeks, then, after a 4 day washout period, the cats were crossed over to the alternate 3 week treatment. In a second study, 10 CKD cats were randomized to receive 1.88 mg/0.1 ml CTM or placebo on the same schedule. Physical examination and serum biochemistry were performed before and after each treatment period, and owners kept daily logs of appetite, activity and eating behaviors. Mirtazapine concentrations in CTM gels and steady-state mirtazapine serum concentrations were measured using liquid chromatography/tandem mass spectrometry.
resultsAdministration of both 3.75 mg and 1.88 mg CTM resulted in a statistically significant increase in weight ( CONCLUSIONS AND RELEVANCE: CTM increased appetite and resulted in weight gain in CKD cats despite significant inconsistencies in compounding, and may benefit cats in countries where an approved product is not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.